
IDEXX Laboratories Inc
NASDAQ:IDXX

Balance Sheet
Balance Sheet Decomposition
IDEXX Laboratories Inc
Current Assets | 1.4B |
Cash & Short-Term Investments | 288.3m |
Receivables | 561.3m |
Other Current Assets | 550.3m |
Non-Current Assets | 1.9B |
Long-Term Investments | 57.7m |
PP&E | 829.3m |
Intangibles | 516.8m |
Other Non-Current Assets | 489.8m |
Balance Sheet
IDEXX Laboratories Inc
Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | ||
---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||
Cash & Cash Equivalents |
129
|
155
|
188
|
124
|
90
|
384
|
145
|
113
|
454
|
288
|
|
Cash Equivalents |
129
|
155
|
188
|
124
|
90
|
384
|
145
|
113
|
454
|
288
|
|
Short-Term Investments |
214
|
237
|
284
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Total Receivables |
200
|
232
|
270
|
273
|
308
|
375
|
426
|
491
|
530
|
561
|
|
Accounts Receivables |
188
|
205
|
235
|
259
|
287
|
355
|
406
|
443
|
513
|
534
|
|
Other Receivables |
12
|
28
|
36
|
14
|
21
|
19
|
20
|
48
|
17
|
27
|
|
Inventory |
189
|
158
|
164
|
173
|
195
|
210
|
269
|
368
|
380
|
382
|
|
Other Current Assets |
90
|
64
|
66
|
84
|
87
|
94
|
117
|
130
|
132
|
168
|
|
Total Current Assets |
822
|
846
|
972
|
654
|
680
|
1 063
|
956
|
1 102
|
1 495
|
1 400
|
|
PP&E Net |
333
|
357
|
379
|
437
|
615
|
646
|
693
|
768
|
818
|
829
|
|
PP&E Gross |
333
|
357
|
379
|
437
|
615
|
646
|
693
|
768
|
818
|
829
|
|
Accumulated Depreciation |
346
|
385
|
433
|
469
|
519
|
587
|
648
|
706
|
785
|
835
|
|
Intangible Assets |
56
|
46
|
44
|
42
|
59
|
53
|
99
|
98
|
85
|
112
|
|
Goodwill |
179
|
178
|
200
|
215
|
240
|
243
|
359
|
362
|
366
|
405
|
|
Note Receivable |
0
|
0
|
0
|
31
|
81
|
98
|
124
|
150
|
168
|
186
|
|
Long-Term Investments |
12
|
11
|
10
|
11
|
14
|
12
|
19
|
56
|
56
|
58
|
|
Other Long-Term Assets |
73
|
92
|
109
|
147
|
145
|
180
|
188
|
213
|
272
|
304
|
|
Other Assets |
179
|
178
|
200
|
215
|
240
|
243
|
359
|
362
|
366
|
405
|
|
Total Assets |
1 475
N/A
|
1 531
+4%
|
1 713
+12%
|
1 537
-10%
|
1 833
+19%
|
2 295
+25%
|
2 437
+6%
|
2 747
+13%
|
3 260
+19%
|
3 293
+1%
|
|
Liabilities | |||||||||||
Accounts Payable |
53
|
60
|
67
|
70
|
72
|
75
|
116
|
110
|
111
|
114
|
|
Accrued Liabilities |
185
|
211
|
224
|
234
|
289
|
373
|
416
|
385
|
392
|
440
|
|
Short-Term Debt |
573
|
611
|
655
|
399
|
289
|
0
|
74
|
579
|
250
|
250
|
|
Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
50
|
75
|
75
|
75
|
168
|
|
Other Current Liabilities |
46
|
52
|
59
|
69
|
76
|
85
|
83
|
87
|
124
|
96
|
|
Total Current Liabilities |
857
|
935
|
1 005
|
770
|
725
|
583
|
764
|
1 236
|
952
|
1 068
|
|
Long-Term Debt |
500
|
499
|
500
|
500
|
600
|
859
|
775
|
694
|
623
|
450
|
|
Deferred Income Tax |
49
|
39
|
25
|
29
|
33
|
12
|
9
|
8
|
7
|
11
|
|
Minority Interest |
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Other Liabilities |
153
|
166
|
238
|
247
|
297
|
209
|
200
|
200
|
194
|
169
|
|
Total Liabilities |
1 559
N/A
|
1 639
+5%
|
1 768
+8%
|
1 547
-12%
|
1 655
+7%
|
1 663
+0%
|
1 747
+5%
|
2 138
+22%
|
1 775
-17%
|
1 698
-4%
|
|
Equity | |||||||||||
Common Stock |
16
|
16
|
16
|
15
|
15
|
15
|
16
|
16
|
16
|
17
|
|
Retained Earnings |
318
|
540
|
804
|
1 168
|
1 596
|
2 176
|
2 920
|
3 600
|
4 445
|
5 332
|
|
Additional Paid In Capital |
941
|
1 012
|
1 074
|
1 138
|
1 214
|
1 295
|
1 377
|
1 463
|
1 570
|
1 674
|
|
Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
Treasury Stock |
1 316
|
1 633
|
1 912
|
2 289
|
2 601
|
2 800
|
3 571
|
4 392
|
4 475
|
5 334
|
|
Other Equity |
42
|
43
|
36
|
42
|
46
|
53
|
53
|
78
|
71
|
94
|
|
Total Equity |
84
N/A
|
108
-29%
|
54
+50%
|
10
+82%
|
178
N/A
|
632
+256%
|
690
+9%
|
609
-12%
|
1 485
+144%
|
1 595
+7%
|
|
Total Liabilities & Equity |
1 475
N/A
|
1 531
+4%
|
1 713
+12%
|
1 537
-10%
|
1 833
+19%
|
2 295
+25%
|
2 437
+6%
|
2 747
+13%
|
3 260
+19%
|
3 293
+1%
|
|
Shares Outstanding | |||||||||||
Common Shares Outstanding |
90
|
88
|
87
|
86
|
86
|
85
|
85
|
83
|
83
|
82
|